This analysis of the TRINITY study (Triple Therapy
with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in
Hypertensive Patients
Study) also demonstrated that the investigational
triple combination therapy (40/10/25 mg) enabled more patients with
hypertension and diabetes to achieve blood pressure goal of
<130/80 mm Hg at week 12 as compared to corresponding dual
combination therapies (41.1 percent in the triple combination group
versus 10.1 to 16.3 percent in the dual combination groups, P less
than or equal to 0.0002).(1) Baseline blood pressures for those
patients receiving the triple combination therapy and corresponding
dual combination therapies were 170.7/98.3 mm Hg and
170.7-173.1/97.8-99.3 mm Hg, respectively.(1)